Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with basiliximab and cyclosporine withdrawal vs cyclosporine minimization in de novo kidney transplant recipients (12‑month study)
2005-000380-26Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2006
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, basiliximab and cyclosporine (2 arms), sponsored by Novartis. Primary endpoints: Glomerular filtration rate (GFR) at month 12 post-transplant, Serum creatinine at month 12 post-transplant and 1 more. Started May 2006; status: completed.
02
Drugs
everolimusbasiliximabcyclosporine
Beyond the preview
Go deeper on 2005-000380-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000380-26.